Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Irish Pharmaceutical Healthcare Association .
Filed returns
25
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Irish Pharmaceutical Healthcare Association | Health | EU Presidency Associated event with Commission VarHelyi on European Competitiveness and the role of Life Sciences and the Pharmaceutical Industry. (Public policy or programme) | 7 | On lobbying.ie |
| May–Aug 2026 | Irish Pharmaceutical Healthcare Association | Health | Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | Industry position on a National Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | New framework Agreement on the Pricing and Supply of Medicines. (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | New framework Agreement on the Pricing and Supply of Medicines. (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | US-EU Trade Tariffs (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | A National Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | Moving Codeine containing OTC medicines from pharmacy only to prescription. (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Future Framework Agreement (Legislation) | 6 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on access to medicines in EU smaller countries/markets and intellectual property rights. (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual property rights. (ii) Proposed Life Sciences Strategy. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual Property rights; (ii) Industry position on a National Life Sciences Strategy; (iii) EU and Irish… (Legislation) | 4 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revisions of EU General Pharmaceutical Legislation and (ii) Irish Government Position on intellectual property rights. (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual Property rights; (ii) Industry position on a National Life Sciences Strategy; (iii) EU and Irish… (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revisions of EU General Pharmaceutical Legislation and (ii) Irish Government Position on intellectual property rights. (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Issues concerning the timely reimbursement of medicines in Ireland. (Public policy or programme) | 12 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | EU Commission proposed revision of the EU General Pharmaceutical Legislation and related matters, with particular attention to intellectual property rights provisions, competitiveness and regulatory affairs. (Legislation) | 8 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | Issues concerning the timely reimbursement of medicines in Ireland. (Public policy or programme) | 13 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | European Commission Urban Waste Water Treatment Directive (UWWTD), with particular attention to the polluter payers principal and proportional responsibility. (Legislation) | 8 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation, particularly items relating to incentives/intellectual property rights; (ii) EU wide access to new medicines. (Legislation) | 10 | On lobbying.ie |
| Jan–Apr 2024 | Irish Pharmaceutical Healthcare Association | Health | (1) Budget 2024 - the need for funding of new medicines. (2) Likely no provision for new developments funding to HSE for new medicines in Budget 2024. (3) Absence of funding for new medicines in Budget 2024. (4)… (Matters involving public funds) | 34 | On lobbying.ie |
| Jan–Apr 2023 | Irish Pharmaceutical Healthcare Association | Health | Revision of pharmaceutical legislation by European Commission. (Legislation) | 10 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | Congratulations on appointment. Seek support for fast access to new medicines and for innovation in the EU Pharmaceutical Strategy. (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | Forum, 'The Future of Medicines' (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | Security of energy supply in the context of the war on Ukraine and the biopharmaceutical industry's exposure to any potential outages. (Public policy or programme) | 1 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 25 | 100.0% |